[A18-67] Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2019
Commission awarded on 02.10.2018 by the Federal Joint Committee (G-BA).
Head and neck squamous cell carcinoma
Advantage in overall survival, disadvantages in some side effects; hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.